Navigation Links
CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Date:10/12/2009

in. Without C1-INH, patients with HAE suffer from recurrent episodes of rapid swelling of areas of the skin and underlying tissues including the face, mouth and abdomen. Berinert( )is a unique HAE therapy because of its reliable record of proven efficacy and safety in international clinical use in over 400,000 treatments in Germany, Austria, Switzerland, and several other countries where it is manufactured and sold by CSL Behring under the trade name Berinert® P.

Important Safety Information

Berinert is a plasma derived concentrate of C1 Esterase Inhibitor (Human), indicated for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE) in adult and adolescent patients.

The safety and efficacy of Berinert for prophylactic therapy have not been established. Berinert is contraindicated in individuals who have had an anaphylactic or severe systemic reaction to C1-INH preparations. Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis). If hypersensitivity is suspected, immediately discontinue administration and initiate appropriate treatment. Epinephrine should be immediately available for treatment of acute severe hypersensitivity reactions.

Thrombotic events have occurred in patients receiving off-label high doses of Berinert. Monitor patients with known risk factors for thrombotic events.

Berinert is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most serious adverse reaction reported in subjects in clinical studies who received Berinert is an increase in the severity of pain associated with HAE. The most common adverse reactions observed in more than 4 percent of subjects after Berinert treatment wer
'/>"/>

SOURCE CSL Behring
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
2. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
5. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
6. Child Neurology Foundation Announces the Launch of Infantilespasmsinfo.org
7. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
8. Onyx Pharmaceuticals Announces Investor Teleconference and Webcast
9. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
10. ADVENTRX Pharmaceuticals Announces Closing of Financing
11. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014   Mast Therapeutics, Inc. (NYSE MKT: ... Edwin L. Parsley , D.O. has joined the Company ... Dr. Parsley has been actively engaged with ... February 2014.  He has served as Mast,s interim Chief ... Officer of Aires since April 2011.  Dr. Parsley previously ...
(Date:10/2/2014)... Oct. 1, 2014   Intarcia Therapeutics, Inc. ... four phase 3 clinical trials for ITCA 650 (exenatide, ... subcutaneous osmotic mini-pump). The first trial, FREEDOM-1, was a ... efficacy and safety of ITCA 650 in patients with ... 650 to be significantly superior to placebo for both ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
(Date:10/2/2014)... October 02, 2014 BamboofloorChina.com is a ... products have won great appreciation from the global customers ... working hard to make more excellent items. All its ... to help all clients. , The company has ... to its website. Furthermore, the company’s marketing specialist ...
(Date:10/2/2014)... Oct. 1, 2014 (HealthDay News) -- Children with autism ... they,re fully capable of being more active, a small ... levels of 29 children, some with autism and some ... day of moderate physical activity and 70 more minutes ... 17 children with autism scored lower on strength, but ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. ... of Columbia now have a total of 500 confirmed cases ... infecting children since the summer, U.S. health officials reported ... in recent weeks, but it,s not clear what role -- ... said. Health officials are also trying to determine if ...
(Date:10/1/2014)... A new research study published today in the ... in patients older than 50 years with moderate or ... benefit. , Researchers from the University of Melbourne randomly ... knee pain to no acupuncture or sham or pretend ... weeks with participants and acupuncturists blinded to laser and ...
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... and neck cancer that targets multiple peptides (parts of ... ,The researchers created the vaccine to ... mutated in most cancers and associated with poor clinical ... expresses unaltered, or "wild-type," p53 peptides in tumors. When ...
... critical genetic factor in the control of many aspects ... a genetic factor// , called a microRNA, in animal ... differentiation and development. ,MicroRNAS, or miRNAs, ... fine-tune levels of important proteins in cells. To learn ...
... was keenly interested in Buddhism and traveled to India in pursuit ... of 93. ,Born in 1913, Roaf spent his early ... the age of 13 and received a further scholarship in 1931 ... ,In 1934 Roaf's parents moved from London to Liverpool where he ...
... a universal problem. With a view to conserve water, ... the country.// ,In a press release the government ... India is about 1170 mm. However, there is very ... release further said that there had been considerable progress in ...
... Lebanon, a Mediterranean country, is considered notoriously image-conscious. It may ... militants// clashing fiercely all the time. ,But the ... ,Only that should explain why the Fist National Bank ... surgery. ,Its website dubs the 'plastic surgery loans' ...
... series of facts is one thing, understanding the big ... that// relational memory -- the ability to make logical ... is dependent on taking a break from studies and ... sleep. ,Led by researchers at Beth Israel ...
Cached Medicine News:Health News:Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response 2Health News:Scientists Identify Critical Gene Factor in Heart Development 2Health News:Stress on Storage and Conservation of Rain Water by Govt of India 2Health News:Loans for Cosmetic Surgery in Lebanon 2Health News:To Understand the Big Picture, Give It Time -- and Sleep 2Health News:To Understand the Big Picture, Give It Time -- and Sleep 3
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: